Abstract
As biologic drugs are gaining attention worldwide, the biopharmaceutical industry in China has developed rapidly in recent years. The People's Republic of China (PRC) dispute resolution mechanism for drug patents covers chemical drugs, biological products, and traditional Chinese medicines (TCMs). This article delves into the early resolution mechanism for patent disputes of biological products, in conjunction with the patent information and patent statements of biological products registered on the PRC Listed Drug Patent Information Registration Platform. According to the research, a framework for an early resolution mechanism for patent disputes of biological products is established in China. It provides a unified platform for the patent registration and statements. The specific settlement mechanism after patent disputes arise remains to be explored.
Get full access to this article
View all access options for this article.